In conclusion, the assessed panel of markers (apoCIII, MPO, oxidized-apoAI, ceruloplasmin, and PON1) correlates with the reduced anti-inflammatory potential of HDL2 and HDL3 (mostly HDL3 from ACS) isolated from ACS and SA patients and can discriminate between these groups of CAD patients. This evidence concerns the gene MPO and coronary artery disorder.